FDA Approves GW Pharma's CBD Derived Epidiolex to Treat Epilepsy | CashCropToday
0 Shares 713 Views

FDA Approves GW Pharma’s CBD Derived Epidiolex to Treat Epilepsy

June 25, 2018
713 Views

The United States Food & Drugs Administration (FDA) has officially approved GW Pharmaceuticals’ (NASDAQ: GWPH) Cannabidiol (CBD) derived medication called Epidiolex. The newly approved drug is a oral solution that is used for the reduction of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

The new CBD derived pharmaceutical will be available to patients through a medical doctors perception for individuals 2 years old or older that suffer from these life crippling diseases.

The approval process has take place over the past few years. The FDA has conducted a series of randomized clinical trials with hundreds of patients suffering from Lennox-Gastaut syndrome and Dravet syndrome. The results found Epidiolex, in conjunction with other medications, to be an efficient solution in the reduction of seizures associated with these conditions.

This announcement should be observed as a huge step forward in the public’s perception of the  cannabinoid known as CBD and officially verifies that the compound contains medicinal benefits. Cannabidiol is non-psychoactive and can be extracted from the cannabis and industrial hemp plants but, has yet to be distinguished away from its schedule-1 drug classification by the FDA.

“The difficult-to-control seizures that patients with Dravet syndrome and Lennox-Gastaut syndrome experience have a profound impact on these patients’ quality of life,” said Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “In addition to another important treatment option for Lennox-Gastaut patients, this first-ever approval of a drug specifically for Dravet patients will provide a significant and needed improvement in the therapeutic approach to caring for people with this condition.”

You may be interested

KushCo Holdings Announces 2018 Revenue of $51M
Manufacturing
10 views
Manufacturing
10 views

KushCo Holdings Announces 2018 Revenue of $51M

Editor - September 18, 2018

KushCo Holdings, Inc. (OTCQB: KSHB) reported this morning that the company has been able to generate a total $51 million dollars in revenue for the year of 2018,…

CashCropToday | Joint Venture Interviews Justin Braune Part 1
CCT Streaming Shows
22 views
CCT Streaming Shows
22 views

CashCropToday | Joint Venture Interviews Justin Braune Part 1

Ricky M - September 18, 2018

In this episode of Joint Venture, Michael Parker sits down with Justin Braine, Blunt Capital Co. Advisor, to discuss bridging the gap between Cannabis & Hemp Entrepreneurs…

CannTrust Completes First Shipment of Cannabis Oil to Denmark Partner STENOCARE
Global
9 views
Global
9 views

CannTrust Completes First Shipment of Cannabis Oil to Denmark Partner STENOCARE

Editor - September 18, 2018

CannTrust Holdings Inc. (TSX :TRST ) announced this morning that the company has completed its first international shipment of cannabis oils based products to STENOCARE, a Danish company…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: